TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03894540
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: An intravenous solution in single-use vial to be diluted for infusion.
Study: NCT03894540
Drug: IPN60090 single administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsules given once
Study: NCT01850381
Drug: GM608
Normalized name: GM608
DrugBank: Alirinetide (DB17007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For GM608: 320 mg/dose reconstituted with 6.4 mL bacteriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
Study: NCT00693992
Drug: Sunitinib Malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03876041
Drug: Dexamethasone phosphate
Normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous solution for injection
Study: NCT02525133
Drug: XaraColl
Normalized name: Xaracoll
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgical implantation of 3 bupivacaine collagen implants
Study: NCT01054729
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir tablet(s) administered orally once daily
Study: NCT01054729
Drug: PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
Study: NCT01054729
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Study: NCT03876067
Drug: Ozone
Normalized name: OZONE
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Our procedures for O3T application in CBP surgery conform to international guidelines of the ''Madrid Declaration on Ozone Therapy'' 32 . M-O3T will be carried out as follows:~50mL of blood drawn by vacuum from the patient central catheter into a sterile blood transfusion bag in which 10 mL of 3.8% Na citrate solution (Galenica Senese Industries, Siena, Italy) as an anticoagulant will be previously added so that the blood/citrate volume ratio was 9:1. After blood withdrawal, the bag will momentarily disconnected leaving the venous access open by a saline infusion 33 . A corresponding volume (50 mL) of gas was immediately added with an O3 concentration of 20-50 micrograms/mL gas. Ozone was produced by Medozon compact generator (Herrmann Apparatebau GmbH, Germany).~At this point, the hyper-oxygenated ozonated blood will be mixed with the cold cardioplegia (Thomsons cardioplegia) this amount of ozonated blood will be added to each 500 ml of cardioplegic solution
Study: NCT03876067
Drug: Cardioplegic Solutions
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in which in which only cold blood cardioplegia
Study: NCT04603924
Drug: Niclosamide
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niclosamide is an antihelmintic with in-vitro antiviral activity
Study: NCT02783404
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receiving 2 gr oral Amoxicillin before dental any manipulation and following endotracheal intubation
Study: NCT02783404
Drug: Amoxicillin-Potassium Clavulanate
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receiving 2 gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate
Study: NCT02403310
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction: Oral selinexor on days 1, 3, 8, 10, 15 and 17.~* Dose Level 2: 80 mg twice weekly.~* Dose Level 1 (starting dose): 60 mg twice weekly.~* Dose Level -1: 40 mg twice weekly.~Consolidation: Selinexor same dose as induction (days 1,3,8,10) unless dose limiting toxicity (DLT) dictates a dose reduction.~Maintenance: Selinexor at the same dose as induction on days 1 and 8 a 21 day cycle. They will continue for a maximum of 12 months.
Study: NCT01479049
Drug: MP (moderate potassium) group
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hearts were arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L)during cardiac operation
Study: NCT01625169
Drug: Etravirine pharmacokinetics in breast milk and plasma
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HIV+ pregnant women will receive etravirine 200mg PO BID for 14 days postpartum. PK will be done on postpartum days 5 and 14.
Study: NCT02441803
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3.
Study: NCT02441803
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 10 mg/m2 by vein on Days -6 to -3.
Study: NCT02441803
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salvage Chemotherapy Before Transplant: Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Clofarabine 40 mg/m2 by vein on Days -6 to -3.
Study: NCT02441803
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2.
Study: NCT02441803
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5.
Study: NCT02441803
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.
Study: NCT02441803
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2 by vein on Days 1 - 5.
Study: NCT02441803
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 g/m2 by vein on Days 6 - 10.
Study: NCT02441803
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2 by vein on Days 6 - 8.
Study: NCT02398123
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00824538
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03065530
Drug: Dexmedetomidine 0.03ug/kg/h
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.03ug/kg/h Dexmedetomidine after cesarean section.
Study: NCT03065530
Drug: Dexmedetomidine 0.05ug/kg/h
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.05ug/kg/h Dexmedetomidine after cesarean section.
Study: NCT03065530
Drug: Dexmedetomidine 0.08ug/kg/h
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.08ug/kg/h Dexmedetomidine after cesarean section.
Study: NCT00950027
Drug: povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oropharyngeal decontamination every 4 hours
Study: NCT02873221
Drug: Ubrogepant
Normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Study: NCT02873221
Drug: Placebo-matching Ubrogepant
Normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.
Study: NCT01325493
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
Study: NCT04341610
Drug: Stem Cell Product
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline
Study: NCT01305369
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be blindly and randomly allocated to treatment A (prasugrel 10 mg daily) or B (placebo) for 15 days. After a 15-day wash-out period, patients who had initially been allocated to treatment A will be allocated to treatment B, and vice versa.
Study: NCT00294346
Drug: AV608
Normalized name: AV608
DrugBank: AV608 (DB05072)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00956644
Drug: irbesartan/amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning
Study: NCT00956644
Drug: amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning
Study: NCT01142648
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugammadex 200 mg iv, single dose, bolus.
Study: NCT01142648
Drug: Neostigmine and glycopyrrolate
Normalized name: glycopyrrolate / neostigmine Injectable Solution
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neostigmine 2.5 mg and glycopyrrolate 0,5 mg, iv, single dose, bolus, diluted in 2 ml volume with saline
Study: NCT00142103
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
Study: NCT02403310
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: Daunorubicin 60 mg/m\^2/day (days 1-3).~Consolidation: Daunorubicin 45 mg/m\^2/day (days 1-2).
Study: NCT02403310
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: Cytarabine 100 mg/m\^2/day (days 1-7).~Consolidation: Cytarabine 100 mg/m\^2/day (continuous infusion on days 1-5).
Study: NCT02203019
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol will be administered for sedation in mechanically ventilated patients with sepsis.
Study: NCT02203019
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine will be administered for sedation in mechanically ventilated patients with sepsis.
Study: NCT04221516
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 200mg every 21 days (3 weeks) for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy.
Study: NCT01430195
Drug: Afamelanotide
Normalized name: Afamelanotide
DrugBank: Afamelanotide (DB04931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation Other Name: CUV1647
Study: NCT02556762
Drug: PF
Normalized name: PFT
DrugBank: Bentiromide (DB00522)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy: Cisplatin and 5fluorouracil
Study: NCT02853435
Drug: Gepotidacin RC Tablet
Normalized name: gepotidacin
DrugBank: Gepotidacin (DB12134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The tablet is a capsule shape white film coated tablet with no identifying markings. This is an immediate release tablet containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
Study: NCT04579393
Drug: fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The study intervention is fostamatinib, an inhibitor of spleen tyrosine kinase that will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses. Subjects will receive standard of care and be randomized to receive fostamatinib or matching placebo.
Study: NCT00907738
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
Study: NCT00539721
Drug: Rolapitant Dose 1
DrugBank: Rolapitant (DB09291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Study: NCT00539721
Drug: Rolapitant Dose 2
DrugBank: Rolapitant (DB09291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Study: NCT00539721
Drug: Rolapitant Dose 3
DrugBank: Rolapitant (DB09291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Study: NCT00539721
Drug: Rolapitant Dose 4
DrugBank: Rolapitant (DB09291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Study: NCT00539721
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1
Study: NCT04146532
Drug: Aspirin 500 MG
Normalized name: aspirin 500 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single 500mg aspirin capsule.
Study: NCT00489983
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00489983
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00163137
Drug: lasofoxifene
Normalized name: lasofoxifene
DrugBank: Lasofoxifene (DB06202)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: lasofoxifene 0.25mg
Study: NCT00163137
Drug: raloxifene
Normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: raloxifene 60 mg/day
Study: NCT03490786
Drug: GT-001
Normalized name: GTS-21
DrugBank: GTS-21 (DB05708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK, PD Study to Determine Safety of Escalating Doses of GT-001
Study: NCT03364998
Drug: Damoctocog (Jivi, BAY94-9027)
Normalized name: damoctocog alfa pegol Injection [Jivi]
DrugBank: Damoctocog alfa pegol (DB14700)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 international units (IU)/kg, given as a 10 minute injection, 1 dose
Study: NCT03364998
Drug: Elocta
Normalized name: Eloctate
DrugBank: Efmoroctocog alfa (DB11607)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 60 IU/kg, given as a 10 minute injection, 1 dose
Study: NCT01707147
Drug: Trajenta tablet
Normalized name: Tradjenta
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin
Study: NCT00772967
Drug: Ultracet
Normalized name: Ultracet
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Study: NCT00793585
Drug: allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level \< 6mg/dl , the dosage changed to 200mg/d.
Study: NCT02795156
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
Study: NCT02795156
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
Study: NCT02795156
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
Study: NCT01936337
Drug: DLX105 Hydrogel
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical administration on psoriatic plaque
Study: NCT03385356
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation of 1000IU vs 4000IU vitamin D per day for four months during winter time, when levels of vitamin D in serum of MS patients are especially low.
Study: NCT00404040
Drug: Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)
Normalized name: polyethylene glycol 3350 / potassium chloride / sodium bicarbonate / sodium chloride
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00404040
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02707757
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1gram of iron sucrose (5 200mg aliquots) administered if participant's haemoglobin is less than 9.5g/dl
Study: NCT00033839
Drug: Civamide (Zucapsaicin)
Normalized name: Capsaicin
DrugBank: Zucapsaicin (DB09120)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01379586
Drug: ONO-4053
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: ONO-4053 doses proposed are 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg as a single dose administered by mouth once daily
Study: NCT04370262
Drug: SOC + Intravenous Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of Care treatment plus IV famotidine
Study: NCT00046826
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00046826
Drug: estramustine phosphate sodium
Normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00046826
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04505410
Drug: Advanced therapy only without dietary intervention
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group will start an advanced therapy and follow a diet solely based on dietary tolerance: new advanced therapy: Tofacitinib and Upadacitinib (JAK inhibitors), Infliximab (anti-TNF), Ustekinumab or Risankizumab (IL-23 inhibitors).
Study: NCT01520792
Drug: Paracetamol (drug)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.
Study: NCT02444169
Drug: Incobotulinumtoxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: An injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.
Study: NCT02585804
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablet, 10mg, PO, 8 weeks
Study: NCT03927729
Drug: Methoxyflurane
Normalized name: Methoxyflurane
DrugBank: Methoxyflurane (DB01028)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pain will be treated with inhaled methoxyflurane (Penthrox®).
Study: NCT02569489
Drug: HBI-8000
Normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02569489
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02569489
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04653415
Drug: Gabapentin 300mg
Normalized name: GABAPENTIN 300MG CAP
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone.
Study: NCT04653415
Drug: Methylprednisolone 125 mg
Normalized name: methylprednisolone 125 MG
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone.
Study: NCT04155710
Drug: Low dose IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 doses of subcutaneous (SC) LD-IL-2 (9 MIU every 8-12 hours) will follow the infusion of IOV-2001